Business Wire

Chugai Presents Results of Two Pivotal Phase lll Studies for its Bispecific Antibody HEMLIBRA® at WFH 2018

Jaa

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) today announced that full results from HAVEN 3 study (NCT02847637) and HAVEN 4 study (NCT03020160) evaluating Chugai’s hemophilia A treatment HEMLIBRA® [generic name: emicizumab (genetical recombination)] are being presented at the World Federation of Hemophilia 2018 World Congress held in Glasgow, Scotland from May 20 to 24. HAVEN 3 study is conducted in people with hemophilia A without inhibitors, and HAVEN 4 study is conducted in people with hemophilia A with or without inhibitors. Results from both studies will be presented as late-breaking abstracts.

“The results from HAVEN 3 study demonstrate that HEMLIBRA, which was created with Chugai’s proprietary antibody engineering technologies, can reduce the bleeding risk in people with hemophilia A without inhibitors. The intra-patient comparison in this study also shows a statistically significant reduction in bleeding by HEMLIBRA prophylaxis compared to factor VIII therapy, the current standard treatment,” said Chugai’s President & CEO, Tatsuro Kosaka. “In addition, HAVEN 4 data indicates that regardless of the presence of inhibitors, HEMLIBRA administration once every four weeks can reduce the risk of bleeding in people with hemophilia A compared with existing treatments. We will closely work with Roche to obtain approval of HEMLIBRA for the treatment of hemophilia A without inhibitors as early as possible.”

HAVEN 3 Study

Study description

HAVEN 3 study is a randomized, multicentre, open-label phase III study evaluating the efficacy, safety and pharmacokinetics of HEMLIBRA prophylaxis subcutaneous injection once a week and once every two weeks. The study enrolled 152 patients with hemophilia A, 12 years of age or older without inhibitors to factor VIII, who were previously treated with episodic or prophylactic factor VIII therapy.

  • Primary endpoint: number of treated bleeds over time with HEMLIBRA prophylaxis (Arm A and Arm B) versus no prophylaxis (Arm C).
  • Secondary endpoints: all bleed rate, treated spontaneous bleed rate, treated joint bleed rate, treated target joint bleed rate, health-related quality of life (HRQoL) / health status with HEMLIBRA prophylaxis (Arm A and Arm B) versus no prophylaxis (Arm C); intra-patient comparison of bleed rate and safety on their prior prophylactic factor VIII therapy (Arm D); and safety etc.

Study design    n=152

  • Patients previously treated with episodic factor VIII therapy were randomized in a 2:2:1 fashion to either Arm A, B or C
         

Arm A

(n=36)

  Received HEMLIBRA prophylaxis at 3 mg/kg by once-weekly subcutaneous injection for 4 weeks, followed by 1.5 mg/kg once-weekly subcutaneous injection
Arm B

(n=35)

Received HEMLIBRA prophylaxis at 3 mg/kg by once-weekly subcutaneous injection for 4 weeks, followed by 3 mg/kg once every two weeks subcutaneous injection
Arm C

(n=18)

  No prophylaxis control arm
 
  • Patients previously treated with factor VIII prophylactic were enrolled in:
         
Arm D

(n=63)

  Received HEMLIBRA prophylaxis at 3 mg/kg by once-weekly subcutaneous injection for 4 weeks, followed by 1.5 mg/kg once-weekly subcutaneous injection
 

Episodic treatment of breakthrough bleeds with factor VIII therapy was allowed per protocol.

Summary of results

  • HEMLIBRA achieved a statistically significant reduction in treated bleeds by 96% (Wald test, p <0.0001) with once-weekly prophylaxis of HEMLIBRA (Arm A) and 97% (p <0.0001) with once every two weeks prophylaxis respectively, compared with no prophylaxis control arm (Arm C).
       

 [Major secondary endpoints and reduction rate (%)]  (Wald test)

    Arm A   Arm B
All bleeds 95%

(p <0.0001)

94%

(p <0.0001)

Treated spontaneous bleeds 94%

(p <0.0001)

98%

(p <0.0001)

Treated joint bleeds 96%

(p <0.0001)

97%

(p <0.0001)

Treated target joint bleeds   95%

(p <0.0001)

  95%

(p <0.0001)

  • 55.6% (95% CI: 38.1, 72.1) of patients receiving once-weekly prophylaxis of HEMLIBRA (Arm A) experienced zero treated bleeds and 60% (95% CI: 42.1, 76.1) of patients receiving once every two weeks prophylaxis of HEMLIBRA (Arm B) compared to 0% (95% CI: 0.0, 18.5) of those not receiving prophylaxis treatment (Arm C).
  • An intra-patient comparison (n=48) in patients who had previously treated with factor VIII prophylaxis prior to the study (Arm D) and participated in the foregoing non-interventional study (NIS) showed that 68% (RR=0.32, p <0.0001) reduction of treated bleeds with once-weekly prophylaxis of HEMLIBRA.
  • Adverse events (AEs) occurring in 5% or more of patients treated with HEMLIBRA were injection site reactions, joint pain (arthralgia), common cold symptoms (nasopharyngitis), headache, upper respiratory tract infection and influenza.
  • There were no unexpected or serious adverse events (AEs) related to HEMLIBRA and most common AE profiles appeared consistent with the known safety profile of the medicine.

HAVEN 4 Study

Study Description

HAVEN 4 study is a single-arm, multicentre, open-label, phase III study evaluating the efficacy, safety, and pharmacokinetics of subcutaneous administration of HEMLIBRA dosed every four weeks. The study included 48 patients (12 years of age or older) with hemophilia A with or without inhibitors to factor VIII who were previously treated with either on-demand or prophylactic factor VIII or bypassing agents, depending on their inhibitor status.

  • Primary endpoint: treated bleed rate with HEMLIBRA prophylaxis
  • Secondary endpoints: all bleed rate, treated spontaneous bleed rate, treated joint bleed rate, treated target joint bleed rate, health-related quality of life (HRQoL) / health status, and safety etc.

Study design    n=48

Patients with or without inhibitors to factor VIII previously treated with either on-demand or prophylactic factor VIII or bypassing agents were enrolled in two cohorts. The study was conducted in two stages as follows;

         
Cohort   Objective   Treatment Regimen
Pharmacokinetic (PK) run-in cohort

(n=7)

Evaluate pharmacokinetics Received HEMLIBRA prophylaxis at 6 mg/kg once every 4 weeks
Expansion cohort

(n=41)

  Evaluate efficacy and safety   Received HEMLIBRA prophylaxis at 3 mg/kg once every week for 4 weeks, followed by 6 mg/kg once every 4 weeks
 

All patients in the PK run-in cohort (n=7) were previously treated with on-demand treatment and then received HEMLIBRA prophylaxis in the study. The evaluation of pharmacokinetics was conducted after monitoring all seven patients in the PK run-in cohort for at least six weeks since they had initiated the administration of HEMLIBRA, followed by an expansion cohort study. Episodic treatment of breakthrough bleeds with factor VIII therapy was allowed per protocol.

Summary of results

  • Patients receiving HEMLIBRA prophylaxis in Expansion cohort had a median annualized bleeding rate (ABR) for treated bleeds of 0.0 (IQR: 0.0; 2.1).
  • 56.1% (95% CI: 39.7, 71.5) of patients in Expansion cohort achieved zero treated bleeds and 90.2% (95% CI: 76.9, 97.3) of patients experienced three or fewer treated bleeds.
 

 

   

[Major secondary endpoints and achievement rate (%) of zero bleeds]

  All bleeds:   29.3% (95% CI: 16.1, 45.5)
Treated spontaneous bleeds: 82.9% (95% CI: 67.9, 92.8)
Treated joint bleeds: 70.7% (95% CI: 54.5, 83.9)
Treated target joint bleeds: 85.4% (95% CI: 70.8, 94.4)
  • Results from HAVEN 4 study is consistent with results obtained from other phase III studies of HEMLIBRA. These data show that once every 4 weeks prophylaxis of HEMLIBRA can provide clinically meaningful control of bleeding in patients with hemophilia A with or without factor VIII inhibitors.
  • There were no unexpected or serious adverse events (AEs) related to HEMLIBRA and the most common AEs were consistent with previous studies.
  • Injection site reaction was the most common AE, occurring in nine people.
 

Summary of the HAVEN 3 (NCT02847637) study results presented at WFH

Study Description   A randomized, multicentre, open-label phase III study evaluating the efficacy, safety and pharmacokinetics of HEMLIBRA prophylaxis subcutaneous injection once a week and once every two weeks.
Patients

Patients with hemophilia A, 12 years of age or older without inhibitors to factor VIII, who were previously treated with episodic or prophylactic factor VIII therapy.

  N=152
Primary endpoint Number of bleeds over time with HEMLIBRA prophylaxis (Arm A and Arm B) versus no prophylaxis (Arm C)
Study group   No prophylaxis

(Arm C; n=18)

  Once weekly HEMLIBRA prophylaxis

(Arm A; n=36)

  Once every 2 weeks HEMLIBRA prophylaxis

(Arm B; n=35)

Treated bleeds (primary endpoint)
Median efficacy period, weeks

(min–max)

24.0

(14.4–25.0)

  29.6

(17.3–49.6)

  31.3

(7.3–50.6)

Model-based ABR (95% CI)* 38.2

(22.9; 63.8)

1.5

(0.9; 2.5)

1.3

(0.8; 2.3)

% reduction vs arm C

(RR, Wald test; p-value)

N/A 96% reduction

(0.04, p <0.0001)

97% reduction

(0.03, p <0.0001)

Median ABR

(Interquartile range; IQR)

40.4

(25.3; 56.7)

0.0

(0.0; 2.5)

0.0

(0.0; 1.9)

% patients with zero bleeds

(95% CI)

0.0

(0.0; 18.5)

55.6

(38.1; 72.1)

60

(42.1; 76.1)

% patients with zero to three bleeds

(95% CI)

  5.6

(0.1; 27.3)

  91.7

(77.5; 98.2)

  94.3

(80.8; 99.3)

 
Treated bleeds ABR intra-patient comparison

(Arm D patients who participated in NIS, n=48; secondary endpoint)

Study group   Prior factor VIII prophylaxis

(Arm C; n=48)

  Once-weekly HEMLIBRA prophylaxis

(Arm D; n=48)

Median efficacy period, weeks

(min–max)

30.1

(5.0–45.1)

33.7

(20.1–48.6)

Model-based ABR*

(95% CI)

4.8

(3.2; 7.1)

1.5

(1.0; 2.3)

% reduction vs NIS Factor VIII

(RR, p-value)

68% reduction

(0.32, p <0.0001)

Median ABR (IQR) 1.8

(0.0; 7.6)

0.0

(0.0; 2.1]

% patients with zero bleeds 39.6

(25.8; 54.7)

54.2

(39.2; 68.6)

% patients with zero to three bleeds   72.9

(58.2; 84.7)

  91.7

(80.0; 97.7)

*Negative binomial regression model

 

Summary of the HAVEN 4 (NCT03020160) study results presented at WFH

Study Description   A single-arm, multicentre, open-label, phase III study evaluating the efficacy, safety, and pharmacokinetics of subcutaneous administration of HEMLIBRA dosed every four weeks.
Patients

12 years of age or older patients with hemophilia A with or without inhibitors to factor VIII who were previously treated with either on-demand or prophylactic factor VIII or bypassing agents, depending on their inhibitor status.
N=48

Primary endpoint bleed rate with HEMLIBRA prophylaxis
Study group   HEMLIBRA prophylaxis (n=48 total; n=41 included in efficacy analyses)
Treated bleeds (primary endpoint)
ABR, model based

(95% CI)

2.4

(1.4; 4.3)

Median ABR,

calculated

(IQR)

0.0

(0.0; 2.1)

% patients with zero bleeds

(95% CI)

56.1

(39.7; 71.5)

% patients with zero to three bleeds

(95% CI)

  90.2

(76.9; 97.3)

 

About Chugai

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2016 of Chugai totalled 491.8 billion yen and the operating income was 80.6 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english.

Trademarks used or mentioned in this release are protected by law.

Contact information

For Media
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
Tomoko Shimizu
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
***
For US media
Chugai Pharma USA Inc.
Casey Astringer
Tel: +1-908-516-1350
E-mail: pr@chugai-pharm.com
***
For European media
Chugai Pharma France SAS
Nathalie Leroy
Tel: +33-1-56-37-05-21
E-mail: pr@chugai.eu
***
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou
Tel: +886-2-2715-2000
E-mail: pr@chugai.com.tw
***
For Investors
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 13:45Tiedote

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 12:10Tiedote

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting21.10.2018 01:30Tiedote

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 20:37Tiedote

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10Tiedote

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme